Hyperkalemia and the Risks of Adverse Cardiovascular Outcomes in Patients With Chronic Kidney Disease
Among patients with CKD stages 3b/4, patients with hyperkalemia experienced significantly higher risks of major adverse cardiovascular events and arrhythmia in hospital settings relative to patients without hyperkalemia.
Authors
- Abiy Agiro (ORCID: https://orcid.org/0000-0002-2369-8507)
- Elaine Louden (ORCID: https://orcid.org/0000-0003-1231-2223)
- Erin Cook (ORCID: https://orcid.org/0000-0001-9737-9130)
- Glenn M. Chertow (ORCID: https://orcid.org/0000-0002-7599-0534)
- Ellen Colman
- Angela Zhao (ORCID: https://orcid.org/0009-0004-5019-9094)
- Alexandra Greatsinger (ORCID: https://orcid.org/0000-0001-8576-8614)
- Fan Mu (ORCID: https://orcid.org/0000-0003-0252-0387)
- Jingyi Chen (ORCID: https://orcid.org/0009-0007-0141-2241)
- Pooja Desai (ORCID: https://orcid.org/0000-0002-9546-0901)
Institutions
- AstraZeneca (United States) (US)
- Analysis Group (United States) (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2024-12-25
- DOI
- https://doi.org/10.1161/jaha.124.035256
- Citations
- 3
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- AstraZeneca